Clinical Trials Directory

Trials / Completed

CompletedNCT02975960

ADMSCs for the Treatment of Systemic Sclerosis

Adipose Tissue-derived Mesenchymal Stem Cells for Cell-based Therapy in the Treatment of Systemic Sclerosis

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
7 (actual)
Sponsor
The Catholic University of Korea · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Systemic sclerosis (SSc) is a rare autoimmune disease, mainly characterized by cutaneous and visceral fibrosis. Digital ulcer and sclerosing skin are commonly affected on hands, but the treatment for these manifestations are often ineffective. Adipose tissue contains stromal vascular fraction (SVF), which is abundant multipotent stem cells, capable of tissue repair. A prior study (NCT01813279) has shown the safety and tolerance at 6 months of the subcutaneous injection of SVF in the fingers in SSc. There are only few ways to manage SSc patients with skin lesion who already have treated with several medications (including vasodilators, PDE5 inhibitor, endothelin receptor antagonist) but some times their skin lesions are critical physically and emotionally. Autologous SVF injection could be one of the treatment options to treat skin lesion of SSc. Thus, the investigators study the efficacy and potential adverse event in Korean patients with SSc.

Detailed description

In this study, the investigators will inject autologous Stromal vascular fraction. 1\) Acquiring autologous stromal vascular fraction by plastic surgeon 1. Liposuction 2. Extraction and purifying SVF using Smart-X system (15-20 min) 3. Making syringe filled with autologous SVF 2\) SVF injection Inject SVF subcutaneously with 25G needle in finger

Conditions

Interventions

TypeNameDescription
BIOLOGICALinjection of autologous stromal vascular fraction1. Acquiring autologous stromal vascular fraction (SVF) from liposuction 2. purifying SVF from lipoaspirates and making syringe filled with SVF 3. SVF injection - Inject SVF on fingers subcutaneously.

Timeline

Start date
2016-10-25
Primary completion
2017-10-30
Completion
2018-01-20
First posted
2016-11-29
Last updated
2018-01-25

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT02975960. Inclusion in this directory is not an endorsement.